Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is scheduled to participate in the 7th annual Dawson James Small Cap Growth Conference. Silo Pharma CEO Eric Weisblum will present at the event, which is scheduled for Oct. 12, 2022, in Jupiter, Florida. Weisblum’s presentation will include an overview of Silo Pharma’s acquisition and development of intellectual property and technology rights from leading universities and researchers, including the use of the psychedelic drugs. The presentation will also feature a summary of Silo’s the diversified pipeline, which is focused on underserved rare disease, neurological and mental health indications. Silo’s current therapeutics under development show potential for treatment of Alzheimer’s disease, multiple sclerosis, rheumatoid arthritis, stress-induced psychiatric disorders and fibromyalgia. Weisblum will also be available to meet one-on-one with conference attendees.
To view the presentation, visit https://ibn.fm/ZEh9Z
To view the full press release, visit https://ibn.fm/o3cb5
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research indications such as PTSD, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health-care industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
